Moderna COVID-19 vaccine 94.5% effective in Phase 3 trials, Likely to receive emergency use approval from US FDA

Moderna Inc, one of the leading vaccine manufacturers of the United States, announced on Monday that its vaccine candidate was found 94.5% effective in preventing coronavirus. The results were derived from the third and final phase of trials conducted by the biotechnology company. With a nearly 95 percent success rate, Moderna in its press note sounded hopeful of receiving the emergency use authorisation from FDA.